.: ORİJİNAL ARAŞTIRMA
Adjunctive Role of Some Blood Based Parameters to Serum Prostate Specific Antigen and Its Derivations on Prostate Cancer in Men with ''Gray-Zone'' Prostate Specific Antigen Levels: Prospective Clinical Study
Gri Zondaki Prostat Spesifik Antijen Düzeyleri Olan Erkeklerde Prostat Kanseri Tahmininde Bazı Kan Bazlı Parametrelerin Serum Prostat Spesifik Antijen ve Türevlerine Yardımcı Rolü: Prospektif Klinik Çalışma
J Reconstr Urol. 2022;12(3):120-8
doi: 10.5336/urology.2022-93881
Makale Dili: EN
Tam Metin
ABSTRACT
Objective: To investigate the adjunctive role of some peripheral blood parameters to serum prostate specific antigen (PSA) in predicting the patients with prostate cancer (PCa) prior to prostate biopsy, and clinically significant PCa among those. Material and Methods: This prospective study included men aged ≥45 years, who were scheduled to undergo a prostate biopsy due to gray-zone PSA levels. The levels of free and total PSA (fPSA and tPSA), total testosterone (TT), PSA density (PSAD), C-reactive protein (CRP), De Ritis ratio (aspartate aminotransferase/alanine transaminase) and hemograms were recorded. Patients were divided into 2 groups as benign prostatic hyperplasia (Group 1) and PCa (Group 2) groups. The PCa group was further divided into 2 subgroups as clinically significant and clinically insignificant PCa. The pre-biopsy values of the variables were compared between the groups. Results: A total of 210 patients were included in the study (Group 1, n=105; Group 2, n=105). The mean age was 65.1±7.4 years, the mean tPSA level was 6.14±2.05 ng/mL, and the mean TT level was 15.46±5.47 nmol/L. Age, prostate volume, the values of fPSA, PSAD, CRP, and the ratios of fPSA/tPSA, CRP/albumin and De Ritis were statistically different between the groups. In the PCa group, only the tPSA level was significantly different between the subgroups (p=0.005). The area under curve and the cut-off value for tPSA to predict clinically significant PCa were 0.669 and 5.8 ng/mL, respectively. Conclusion: CRP, the CRP/albumin ratio and De Ritis ratio may further help predict a diagnosis of PCa.
Keywords: Alanine transaminase; aspartate aminotransferases; C-reactive protein; prostate cancer; testosterone
Objective: To investigate the adjunctive role of some peripheral blood parameters to serum prostate specific antigen (PSA) in predicting the patients with prostate cancer (PCa) prior to prostate biopsy, and clinically significant PCa among those. Material and Methods: This prospective study included men aged ≥45 years, who were scheduled to undergo a prostate biopsy due to gray-zone PSA levels. The levels of free and total PSA (fPSA and tPSA), total testosterone (TT), PSA density (PSAD), C-reactive protein (CRP), De Ritis ratio (aspartate aminotransferase/alanine transaminase) and hemograms were recorded. Patients were divided into 2 groups as benign prostatic hyperplasia (Group 1) and PCa (Group 2) groups. The PCa group was further divided into 2 subgroups as clinically significant and clinically insignificant PCa. The pre-biopsy values of the variables were compared between the groups. Results: A total of 210 patients were included in the study (Group 1, n=105; Group 2, n=105). The mean age was 65.1±7.4 years, the mean tPSA level was 6.14±2.05 ng/mL, and the mean TT level was 15.46±5.47 nmol/L. Age, prostate volume, the values of fPSA, PSAD, CRP, and the ratios of fPSA/tPSA, CRP/albumin and De Ritis were statistically different between the groups. In the PCa group, only the tPSA level was significantly different between the subgroups (p=0.005). The area under curve and the cut-off value for tPSA to predict clinically significant PCa were 0.669 and 5.8 ng/mL, respectively. Conclusion: CRP, the CRP/albumin ratio and De Ritis ratio may further help predict a diagnosis of PCa.
Keywords: Alanine transaminase; aspartate aminotransferases; C-reactive protein; prostate cancer; testosterone
ÖZET
Amaç: Biyopsi öncesi biyokimyasal ve hematolojik parametrelerin, prostat kanseri [prostate cancer (PCa)] hastalarını ve bunlardan da klinik anlamlı PCa hastalarını öngörmede prostat spesifik antijene (PSA) yardımcı etkisinin olup olmadığını araştırmaktır. Gereç ve Yöntemler: Çalışmamıza, gri zondaki prostat spesifik antijen (PSA) düzeyleri nedeniyle prostat biyopsisi yapılması planlanan 45 yaş ve üzeri erkekler dâhil edildi. Serbest ve total PSA (sPSA ve tPSA), total testosteron (TT), PSA dansitesi (PSAD), C-reaktif protein (CRP), De Ritis oranı (aspartat aminotransferaz/alanin transaminaz) ve hemogramları kaydedildi. Hastalar benign prostat hiperplazisi (Grup 1) ve PCa (Grup 2) grupları olarak 2'ye ayrıldı. PCa grubu ayrıca klinik anlamlı ve klinik anlamsız PCa olarak 2 alt gruba ayrıldı. Biyopsi öncesi değişkenler gruplar arasında karşılaştırıldı. Bulgular: Çalışmaya toplam 210 hasta dâhil edildi (Grup 1, n=105; Grup 2, n=105). Ortalama yaş 65,1±7,4 yıl, ortalama tPSA seviyesi 6,14±2,05 ng/mL ve ortalama TT seviyesi 15,46±5,47 nmol/L idi. Gruplar arasında yaş, prostat hacmi, sPSA, PSAD, CRP değerleri ve sPSA/tPSA, CRP/albumin ve De Ritis oranları istatistiksel olarak farklı bulundu. PCa grubunda alt gruplar arasında sadece tPSA düzeyi anlamlı olarak farklı bulundu (p=0,005). Klinik olarak anlamlı Pca'yı öngörmek için tPSA'nın eğri altında kalan alan ve cut-off değeri sırasıyla 0,669 ve 5,8 ng/mL idi. Sonuç: CRP, CRP/albumin oranı ve De Ritis oranı, PCa tanısını öngörmede daha fazla yardımcı olabilir.
Anahtar Kelimeler: Alanin transaminaz; aspartat aminotransferazlar; C reaktif protein; prostat kanseri; testosteron
Amaç: Biyopsi öncesi biyokimyasal ve hematolojik parametrelerin, prostat kanseri [prostate cancer (PCa)] hastalarını ve bunlardan da klinik anlamlı PCa hastalarını öngörmede prostat spesifik antijene (PSA) yardımcı etkisinin olup olmadığını araştırmaktır. Gereç ve Yöntemler: Çalışmamıza, gri zondaki prostat spesifik antijen (PSA) düzeyleri nedeniyle prostat biyopsisi yapılması planlanan 45 yaş ve üzeri erkekler dâhil edildi. Serbest ve total PSA (sPSA ve tPSA), total testosteron (TT), PSA dansitesi (PSAD), C-reaktif protein (CRP), De Ritis oranı (aspartat aminotransferaz/alanin transaminaz) ve hemogramları kaydedildi. Hastalar benign prostat hiperplazisi (Grup 1) ve PCa (Grup 2) grupları olarak 2'ye ayrıldı. PCa grubu ayrıca klinik anlamlı ve klinik anlamsız PCa olarak 2 alt gruba ayrıldı. Biyopsi öncesi değişkenler gruplar arasında karşılaştırıldı. Bulgular: Çalışmaya toplam 210 hasta dâhil edildi (Grup 1, n=105; Grup 2, n=105). Ortalama yaş 65,1±7,4 yıl, ortalama tPSA seviyesi 6,14±2,05 ng/mL ve ortalama TT seviyesi 15,46±5,47 nmol/L idi. Gruplar arasında yaş, prostat hacmi, sPSA, PSAD, CRP değerleri ve sPSA/tPSA, CRP/albumin ve De Ritis oranları istatistiksel olarak farklı bulundu. PCa grubunda alt gruplar arasında sadece tPSA düzeyi anlamlı olarak farklı bulundu (p=0,005). Klinik olarak anlamlı Pca'yı öngörmek için tPSA'nın eğri altında kalan alan ve cut-off değeri sırasıyla 0,669 ve 5,8 ng/mL idi. Sonuç: CRP, CRP/albumin oranı ve De Ritis oranı, PCa tanısını öngörmede daha fazla yardımcı olabilir.
Anahtar Kelimeler: Alanin transaminaz; aspartat aminotransferazlar; C reaktif protein; prostat kanseri; testosteron
REFERANSLAR:
- Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol. 2020;77(1):38-52. [Crossref] [PubMed]
- Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317(15):909-16. [Crossref] [PubMed]
- Salman JW, Schoots IG, Carlsson SV, Jenster G, Roobol MJ. Prostate specific antigen as a tumor marker in prostate cancer: biochemical and clinical aspects. Adv Exp Med Biol. 2015;867:93-114. [Crossref] [PubMed]
- Murray NP, Fuentealba C, Reyes E, Lopez MA, Salazar A, Minzer S, et al. Predictive value of neutrophil to lymphocyte ratio in the diagnosis of significant prostate cancer at initial biopsy: a comparison with free percent prostate specific antigen, prostate specific antigen density and primary circulating prostate cells. Asian Pac J Cancer Prev. 2019;20(11):3385-9. [Crossref] [PubMed] [PMC]
- Santotoribio JD, Jimenez-Romero ME. Serum biomarkers of inflammation for diagnosis of prostate cancer in patients with nonspecific elevations of serum prostate specific antigen levels. Transl Cancer Res. 2019;8(1):273-8. [Crossref] [PubMed] [PMC]
- Ha H, Chung JW, Ha YS, Choi SH, Lee JN, Kim BS, et al. Clinical significance of the De Ritis ratio for detecting prostate cancer in a repeat prostate biopsy. Investig Clin Urol. 2019;60(6):447-53. [Crossref] [PubMed] [PMC]
- Lonergan PE, Tindall DJ. Androgen receptor signaling in prostate cancer development and progression. J Carcinog. 2011;10:20. [Crossref] [PubMed] [PMC]
- Schulman CC, Irani J, Morote J, Schalken JA, Montorsi F, Chlosta PL, et al. Testosterone measurement in patients with prostate cancer. Eur Urol. 2010;58(1):65-74. [Crossref] [PubMed]
- Gurbuz C, Canat L, Atis G, Guner B, Caskurlu T. The role of serum testosterone to prostate-specific antigen ratio as a predictor of prostate cancer risk. Kaohsiung J Med Sci. 2012;28(12):649-53. [Crossref] [PubMed]
- Karamanolakis D, Lambou T, Bogdanos J, Milathianakis C, Sourla A, Lembessis P, et al. Serum testosterone: A potentially adjunct screening test for the assessment of the risk of prostate cancer among men with modestly elevated PSA values (> or =3.0 and <10.0 ng/ml). Anticancer Res. 2006;26(4B):3159-66. [PubMed]
- Morote J, Planas J, Ramirez C, Gómez E, Raventós CX, Placer J, et al. Evaluation of the serum testosterone to prostate-specific antigen ratio as a predictor of prostate cancer risk. BJU Int. 2010;105(4):481-4. [Crossref] [PubMed]
- Rhoden EL, Riedner CE, Morgentaler A. The ratio of serum testosterone-to-prostate specific antigen predicts prostate cancer in hypogonadal men. J Urol. 2008;179(5):1741-4. [Crossref] [PubMed]
- Xu L, Hu X, Zhu Y, Lu J, Xu Y, Wang G, et al. Additional value of the ratio of serum total testosterone to total prostate-specific antigen in the diagnosis of prostate cancer in a Chinese population. Andrologia. 2018;50(2). [Crossref] [PubMed]
- Temel MC, Ediz C, Akan S, Ozer E, Yilmaz O. Association of Gleason score with PSA values and serum testosterone levels measured prior to prostate biopsy. J Coll Physicians Surg Pak. 2020;30(4):399-402. [Crossref] [PubMed]
- Haider A, Zitzmann M, Doros G, Isbarn H, Hammerer P, Yassin A. Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registries. J Urol. 2015;193(1):80-6. [Crossref] [PubMed]
- Watts EL, Appleby PN, Perez-Cornago A, Bueno-de-Mesquita HB, Chan JM, Chen C, et al. Low free testosterone and prostate cancer risk: a collaborative analysis of 20 prospective studies. Eur Urol. 2018;74(5):585-94. [Crossref] [PubMed] [PMC]
- Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994;271(5):368-74. [Crossref] [PubMed]
- Corona G, Rastrelli G, Morgentaler A, Sforza A, Mannucci E, Maggi M. Meta-analysis of results of testosterone therapy on sexual function based on international index of erectile function scores. Eur Urol. 2017;72(6):1000-11. [Crossref] [PubMed]
- Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, et al; European Association of Urology. [EAU guidelines on prostate cancer]. Actas Urol Esp. 2009;33(2):113-26. [Crossref] [PubMed]
- Liu ZQ, Chu L, Fang JM, Zhang X, Zhao HX, Chen YJ, et al. Prognostic role of C-reactive protein in prostate cancer: a systematic review and meta-analysis. Asian J Androl. 2014;16(3):467-71. [Crossref] [PubMed] [PMC]
- Kim Y, Jeon Y, Lee H, Lee D, Shim B. The prostate cancer patient had higher C-reactive protein than BPH patient. Korean J Urol. 2013;54(2):85-8. [Crossref] [PubMed] [PMC]
- Toriola AT, Laukkanen JA, Kurl S, Nyyssönen K, Ronkainen K, Kauhanen J. Prediagnostic circulating markers of inflammation and risk of prostate cancer. Int J Cancer. 2013;133(12):2961-7. [Crossref] [PubMed]
- Uchimoto T, Komura K, Fujiwara Y, Saito K, Tanda N, Matsunaga T, et al. Prognostic impact of C-reactive protein-albumin ratio for the lethality in castration-resistant prostate cancer. Med Oncol. 2019;37(1):9. [Crossref] [PubMed]
- Wang H, Fang K, Zhang J, Jiang Y, Wang G, Zhang H, et al. The significance of De Ritis (aspartate transaminase/alanine transaminase) ratio in predicting pathological outcomes and prognosis in localized prostate cancer patients. Int Urol Nephrol. 2017;49(8):1391-8. [Crossref] [PubMed]
- Su S, Liu L, Li C, Zhang J, Li S. Prognostic role of pretreatment de ritis ratio (aspartate transaminase/alanine transaminase ratio) in urological cancers: a systematic review and meta-analysis. Front Oncol. 2020;10:1650. [Crossref] [PubMed] [PMC]
- Karamık K, Aktaş Y, Yıldız A, Erol İ, İslamoğlu E, Ateş M, et al. Predictive role of de ritis ratio in biochemical recurrence after radical prostatectomy. Med Bull Haseki. 2020;58(1):84-93. [Crossref]
- Miller LR, Partin AW, Chan DW, Bruzek DJ, Dobs AS, Epstein JI, et al. Influence of radical prostatectomy on serum hormone levels. J Urol. 1998;160(2):449-53. [Crossref] [PubMed]
- Shin BS, Hwang EC, Im CM, Kim SO, Jung SI, Kang TW, et al. Is a decreased serum testosterone level a risk factor for prostate cancer? A cohort study of korean men. Korean J Urol. 2010;51(12):819-23. [Crossref] [PubMed] [PMC]
- Kwon T, Jeong IG, You D, Park MC, Hong JH, Ahn H, et al. Effect of prostate size on pathological outcome and biochemical recurrence after radical prostatectomy for prostate cancer: is it correlated with serum testosterone level? BJU Int. 2010;106(5):633-8. [Crossref] [PubMed]
- Erol B, Gulpinar MT, Bozdogan G, Ozkanli S, Onem K, Mungan G, et al. The cutoff level of free/total prostate specific antigen (f/t PSA) ratios in the diagnosis of prostate cancer: a validation study on a Turkish patient population in different age categories. Kaohsiung J Med Sci. 2014;30(11):545-50. [Crossref] [PubMed]
.: İşlem Listesi